Trials / Completed
CompletedNCT06068465
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 248 (actual)
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pimavanserin tartrate | pimavanserin tartrate, 34 mg, capsule, once daily by mouth for 6 weeks |
| DRUG | placebo | placebo, capsule, once daily by mouth for 6 weeks |
Timeline
- Start date
- 2024-09-27
- Primary completion
- 2026-02-01
- Completion
- 2026-02-01
- First posted
- 2023-10-05
- Last updated
- 2026-02-27
Locations
27 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06068465. Inclusion in this directory is not an endorsement.